Effective combinations of glucose-lowering drugs in patients with obesity and type 2 diabetes mellitus during the treatment of diabetic foot syndrome
https://doi.org/10.25199/2408-9613-2023-10-2-42-45
Abstract
The article provides a brief analysis of the action mechanisms of modern combinations by glucose-lowering drugs for type 2 diabetes mellitus, diabetic foot syndrome and obesity. Using the example of clinical observations, the positive dynamics of reducing body weight and glycated hemoglobin was demonstrated. It also shows how good control of type 2 diabetes makes it possible to effectively treat such a formidable complication as diabetic foot syndrome.
About the Authors
T. G. Turova
Federal State Budgetary Institution “A. V. Vishnevsky National Medical Research Center of Surgery” Ministry of Health of Russia
Russian Federation
Russian Federation
Turova Tatyana Georgievna – endocrinologist, department of wounds and wound infections of the Department of Wounds and Wound Infections
27 Bolshaya Serpukhovskaya Str., Moscow, 117997
Yu. S. Paskhalova
Federal State Budgetary Institution “A. V. Vishnevsky National Medical Research Center of Surgery” Ministry of Health of Russia ; Federal State Autonomous Educational Institution of Higher Education “Peoples’ Friendship University of Russia” Ministry of Education and Science of Russia
Russian Federation
Russian Federation
Paskhalova Yulia Sergeevna – Candidate of Medical Sciences, senior researcher at the Department of Wounds and Wound Infections, Associate Professor of the Department of Disaster Medicine
8 Miklukho-Maklaya Str., Moscow, 117198
References
1. Салухов В. В., Ильинская Т. А., Минаков А. А. Влияние современной сахароснижающей терапии на массу тела у больных сахарным диабетом 2 типа. Эндокринология: новости, мнения, обучение. 2022; 11 (1): 39–52. [Salukhov V. V., Ilyinskaya T. A., Minakov A. A. The influence of modern glucose-lowering therapy on body weight in patients with type 2 diabetes mellitus = Salukhov V. V., Il’inskaya T. A., Minakov A. A. Vliyaniye sovremennoy sakharosnizhayushchey terapii na massu tela u bol’nykh sakharnym diabetom 2 tipa. Endokrinologiya: novosti, mneniya, obucheniye. 2022; 11 (1): 39–52. (In Russ.)]
2. Галстян Г. Р., Шестакова Е. А., Скляник И. А. Ожирение и сахарный диабет 2 типа: поиск компромиссного терапевтического решения. Сахарный диабет. 2017; 20 (4): 270–278. [Galstyan G. R., Shestakova E. A., Sklyanik I. A. Obesity and type 2 diabetes mellitus: searching for a compromise therapeutic solution = Galstyan G. R., Shestakova Ye. A., Sklyanik I. A. Ozhireniye i sakharnyy diabet 2 tipa : poisk kompromissnogo terapevticheskogo resheniya. Sakharnyy diabet. 2017; 20 (4): 270–278. (In Russ.)]
3. Эндокринология: клинические рекомендации / под ред. акад. РАН И. И. Дедова, акад. РАН Г. А. Мельниченко. М.: ГЭОТАР-Медиа, 2016. С. 253–274, 319–449. [Endocrinology: clinical recommendations = Endokrinologiya: klinicheskiye rekomendatsii / pod red. akad. RAN I. I. Dedova, akad. RAN G. A. Mel’nichenko. M.: GEOTAR-Media, 2016. S. 253–274, 319–449. (In Russ.)]
4. Салухов В. В., Котова М. Е. Основные эффекты, вызываемые ингибиторами SGLT2 у больных сахарным диабетом типа 2, и механизмы, которые их определяют. Эндокринология: новости, мнения, обучение. 2019; 8 (3): 61–74. [Salukhov V. V., Kotova M. E. The main effects caused by SGLT2 inhibitors in patients with type 2 diabetes mellitus and the mechanisms that determine them = Salukhov V. V., Kotova M. E. Osnovnyye effekty, vyzyvayemyye ingibitorami SGLT2 u bol’nykh sakharnym diabetom tipa 2, i mekhanizmy, kotoryye ikh opredelyayut. Endokrinologiya: novosti, mneniya, obucheniye. 2019; 8 (3): 61–74. (In Russ.)]
5. Митиш В. А., Пасхалова Ю. С., Ерошкин И. А., Галстян Г. Р. Гнойнонекротические поражения стопы, критическая ишемия нижних конечностей и сахарный диабет. Неотложная медицинская помощь. 2012; (1): 35–39. [Mitish V. A., Paskhalova Yu. S., Eroshkin I. A., Galstyan G. R. Purulent-necrotic lesions of the foot, critical ischemia of the lower extremities and diabetes mellitus = Mitish V. A., Paskhalova Yu. S., Yeroshkin I. A., Galstyan G. R. Gnoyno-nekroticheskiye porazheniya stopy, kriticheskaya ishemiya nizhnikh konechnostey i sakharnyy diabet. Neotlozhnaya meditsinskaya pomoshch’. 2012; (1): 35–39. (In Russ.)]
6. Малолеткина Е. С., Фадеев В. В., Гурова О. Ю. и др. Оценка качества жизни и удовлетворенности лечением у пациентов с сахарным диабетом 2 типа и морбидным ожирением, получавших различные схемы инсулинотерапии. Эффективная фармакотерапия. 2022; 18 (2): 24–35. [Maloletkina E. S., Fadeev V. V., Gurova O. Yu., et al. Assessment of quality of life and satisfaction with treatment in patients with type 2 diabetes mellitus and morbid obesity receiving various insulin therapy regimens = Maloletkina Ye. S., Fadeyev V. V., Gurova O. Yu. i dr. Otsenka kachestva zhizni i udovletvorennosti lecheniyem u patsiyentov s sakharnym diabetom 2 tipa i morbidnym ozhireniyem, poluchavshikh razlichnyye skhemy insulinoterapii. Effektivnaya farmakoterapiya. 2022; 18 (2): 24–35. (In Russ.)]
7. Байрашева В. К., Пчелин И. Ю., Арефьева А. Н. и др. Новые перспективы применения ингибиторов натрий-глюкозного котранспортера 2 при сахарном диабете. Juvenis Scientia. 2017; (5): 13–19. [Bayrasheva V. K., Pchelin I. Yu., Arefieva A. N., et al. New prospects for the use of sodium-glucose cotransporter 2 inhibitors in diabetes mellitus = Maloletkina Ye. S., Fadeyev V. V., Gurova O. Yu. i dr. Otsenka kachestva zhizni i udovletvorennosti lecheniyem u patsiyentov s sakharnym diabetom 2 tipa i morbidnym ozhireniyem, poluchavshikh razlichnyye skhemy insulinoterapii. Effektivnaya farmakoterapiya. 2022; 18 (2): 24–35. (In Russ.)]
8. Демидова Т. Ю., Алексеева Я. Г. Метаболические и гемодинамические эффекты нового ингибитора натрийглюкозного котранспортера 2-го типа ипраглифлозина при лечении сахарного диабета 2-го типа. АтмосферА. Новости кардиологии 2020; (1): 38–47. [Demidova T. Yu., Alekseeva Ya. G. Metabolic and hemodynamic effects of the new type 2 sodiumglucose cotransporter inhibitor ipragliflozin in the treatment of type 2 diabetes mellitus = Demidova T. Yu., Alekseyeva Ya. G. Metabolicheskiye i gemodinamicheskiye effekty novogo ingibitora natriy-glyukoznogo kotransportera 2-go tipa ipragliflozina pri lechenii sakharnogo diabeta 2-go tipa. AtmosferA. Novosti kardiologii 2020; (1): 38–47. (In Russ.)]
9. Аметов А. С., Гусенбекова Д. Г. Прогрессивная инкретинология: в фокусе β-клетка. Эндокринология: новости, мнения, обучение. 2023; 11 (1): 28–32. [Ametov A. S., Gusenbekova D. G. Progressive incretinology: β-cell in focus = Ametov A. S., Gusenbekova D. G. Progressivnaya inkretinologiya: v fokuse β-kletka. Endokrinologiya: novosti, mneniya, obucheniye. 2023; 11 (1): 28–32. (In Russ.)]
Review
For citations:
Turova T.G., Paskhalova Yu.S. Effective combinations of glucose-lowering drugs in patients with obesity and type 2 diabetes mellitus during the treatment of diabetic foot syndrome. Wounds and wound infections. The prof. B.M. Kostyuchenok journal. 2023;10(2):42-45. (In Russ.) https://doi.org/10.25199/2408-9613-2023-10-2-42-45
Views:
434
Email this article 